Vivani Medical, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $118.6M
- Price
- $1.31
- % Change (Daily % change from the live per-ticker quote feed.)
- +6.05%
- Volume
- 156.9K
About
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.
Quick stats
Shares outstanding90.2M
Computed float41.4M
Float / shares45.9%
Cash runway (months)6.2
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001266806
Websitehttps://www.vivani.com
AI Summary
AI-generated1/13
minorneutralother
Vivani Medical Announces Participation in Upcoming Investor Conferences
Vivani Medical announced plans to participate in two upcoming investor conferences: the Lake Street Capital Markets 10th Annual Best Ideas Growth Conference on September 10, 2026, and the H.C. Wainwright 28th Annual Global Investment Conference on September 14-16, 2026, both in New York.
A pre-recorded company presentation for the H.C. Wainwright conference will be available for viewing starting at 7 a.m. Eastern Time on September 11, 2026, via an online link.
The release contains no new clinical, financial, or strategic disclosures and is standard investor-relations calendar housekeeping for the clinical-stage GLP-1 implant developer.